Screener
Gilead Sciences GILD Finite Lived Intangible Assets - Gross
Finite Lived Intangible Assets - Gross at other companies
Other financials
Where this comes from
Reported directly by Gilead Sciences in its filing.
Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsGross.
The source filing: Gilead Sciences’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:13 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000882095-26-000031
| (in millions) | June 30, 2026 / Gross Carrying Amount | June 30, 2026 / Accumulated Amortization | June 30, 2026 / Foreign Currency Translation Adjustment | June 30, 2026 / Net Carrying Amount | December 31, 2025 / Gross Carrying Amount | December 31, 2025 / Accumulated Amortization | December 31, 2025 / Foreign Currency Translation Adjustment | December 31, 2025 / Net Carrying Amount |
|---|---|---|---|---|---|---|---|---|
| Intangible asset – sofosbuvir | $10,720 | $(8,797) | — | $1,923 | $10,720 | $(8,448) | — | $2,272 |
| Intangible asset – axicabtagene ciloleucel | 7,110 | (3,330) | — | 3,780 | 7,110 | (3,127) | — | 3,983 |
| Intangible asset – Trodelvy | 11,730 | (4,704) | — | 7,026 | 11,730 | (4,164) | — | 7,566 |
| Intangible asset – Hepcludex(1) | 1,395 | (462) | — | 933 | 845 | (415) | — | 430 |
| Other | 1,458 | (1,087) | — | 372 | 1,483 | (1,056) | — | 428 |
| Total finite-lived assets | 32,413 | (18,382) | — | 14,032 | 31,888 | (17,211) | — | 14,678 |
| Indefinite-lived assets – IPR&D(1)(2) | — | — | — | — | 2,300 | — | — | 2,300 |
| Total intangible assets | $32,413 | $(18,382) | — | $14,032 | $34,188 | $(17,211) | — | $16,978 |
Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FAQ
- What is Gilead Sciences's finite lived intangible assets - gross?
- Gilead Sciences (GILD) reported finite lived intangible assets - gross of $32.41B in Q2 2026.
- How has Gilead Sciences's finite lived intangible assets - gross changed year-over-year?
- Gilead Sciences's finite lived intangible assets - gross increased by 1.7% year-over-year, from $31.88B to $32.41B.
- What is the long-term trend for Gilead Sciences's finite lived intangible assets - gross?
- Over 5 years (2020 to 2025), Gilead Sciences's finite lived intangible assets - gross has grown at a 6.8% compound annual growth rate (CAGR), from $22.9B to $31.89B.
- What does finite lived intangible assets - gross mean?
- This metric tracks the total historical cost of intangible assets that have a defined useful life, such as patents, software licenses, or customer relationships. It excludes assets with indefinite lives like certain trademarks or goodwill. It is a key indicator of the company's investment in intellectual property and intangible competitive advantages.
Ask your AI about Gilead Sciences's finite lived intangible assets - gross.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude